VEGFA and myopia: Three studies evaluated the cost-effectiveness of treating pathologic myopia with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) (e.g., ranibizumab, conbercept), and photodynamic therapy (PDT) (Tables 1, 2).